Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

ht loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Tarceva

Tarceva is a once-a-day pill that targets the EGFR pathway. Tarceva is designed to inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cell, one of the critical growth factors in NSCLC and pancreatic cancers. Tarceva is indicated as a monotherapy for patients with locally advanced or metastatic NSCLC whose disease has progressed after one or more courses of chemotherapy. Results from two multicenter, placebo-controlled, randomized Phase 3 trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not recommended in that setting.

In pancreatic cancer, Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced pancreatic cancer, pancreatic cancer that cannot be surgically removed or pancreatic cancer that has spread to distant body organs.

Important Safety Information For Tarceva

There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events including deaths in patients taking Tarceva. Serious side effects (including deaths) in patients taking Tarceva include liver and/
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Barbara, CA (PRWEB) October 25, 2014 ... charity's annual President’s Circle Reception on Monday at the ... FSA’s accomplishments and hear from guest speaker Dr. Winifred ... digital worlds. , Dr. Lender, a Santa Barbara psychologist, ... the challenges and benefits of living in the digital ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... Homeowners that are wondering how they can ... no more. Clean Crawls gives 5 signs of ... when it comes to insulation in their recently released ... by Clean Crawls, can cause problems throughout your entire ... has deteriorated, become damp, or been infested with pests ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2
... Balehonnur-based Central Coffee Research Institute (CCRI) has said that it ... in December 2007 . ,After 21 years of ... December 15. The yet-to-be named hybrid, hi-yielding arabica variety is ... resistant to the widely prevalent white stem borer. ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... the entire Test series against India with a hernia injury.Harmison ... to six weeks, reports BBC . ,England coach ... back and now it's all about getting the operation done ... Chris Tremlett are vying for the third seamer's spot for ...
... government was not averse to inviting the World Health Organisation ... fever in the state that has claimed 173 lives this ... arrived in the state since the outbreak of the fever, ... the fever as chikunguniya and nothing else, we have no ...
... dysfunction can overcome their problem by taking part in ... ,The study also suggests that supplementing sildenafil, ... other names, to group therapy can make the treatment ... sexual function relies on the coordination of psychological, endocrine, ...
... The Punjab University has reserved seats for students suffering from ... ,The University has reserved one seat for each of ... AIDS or suffering from cancer. ,However, the university ... sufficient for the time being, since it do not expects ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
(Date:10/22/2014)... -- Quest Diagnostics (NYSE: DGX ), the world,s ... its Board of Directors has elected Jeffrey M. Leiden, ... 2014. Including Dr. Leiden, the Board has 11 members. ... CEO of Vertex Pharmaceuticals.   Dr. Leiden has more ... the pharmaceutical and biotechnology industries as well as clinical ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... EAST HANOVER, N.J., Aug. 27 The US Food ... tablets, a single-pill for the treatment of high blood ... (aliskiren), with the widely used calcium channel blocker amlodipine. ... are likely to need multiple drugs to achieve their ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ... data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Medicine Technology:Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 3Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 4Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 5Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 6Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 7STALLERGENES: Excellent 1st Half-Year 2010 Performance 2STALLERGENES: Excellent 1st Half-Year 2010 Performance 3STALLERGENES: Excellent 1st Half-Year 2010 Performance 4STALLERGENES: Excellent 1st Half-Year 2010 Performance 5STALLERGENES: Excellent 1st Half-Year 2010 Performance 6STALLERGENES: Excellent 1st Half-Year 2010 Performance 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: